IBDEI0Q6 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11762,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11762,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,11762,1,4,0)
 ;;=4^N05.7
 ;;^UTILITY(U,$J,358.3,11762,2)
 ;;=^5015548
 ;;^UTILITY(U,$J,358.3,11763,0)
 ;;=N05.8^^46^573^50
 ;;^UTILITY(U,$J,358.3,11763,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11763,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,11763,1,4,0)
 ;;=4^N05.8
 ;;^UTILITY(U,$J,358.3,11763,2)
 ;;=^5134085
 ;;^UTILITY(U,$J,358.3,11764,0)
 ;;=N05.9^^46^573^51
 ;;^UTILITY(U,$J,358.3,11764,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11764,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ unspec morphologic changes
 ;;^UTILITY(U,$J,358.3,11764,1,4,0)
 ;;=4^N05.9
 ;;^UTILITY(U,$J,358.3,11764,2)
 ;;=^5134086
 ;;^UTILITY(U,$J,358.3,11765,0)
 ;;=N06.0^^46^573^39
 ;;^UTILITY(U,$J,358.3,11765,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11765,1,3,0)
 ;;=3^Isolated proteinuria w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,11765,1,4,0)
 ;;=4^N06.0
 ;;^UTILITY(U,$J,358.3,11765,2)
 ;;=^5015549
 ;;^UTILITY(U,$J,358.3,11766,0)
 ;;=N06.1^^46^573^38
 ;;^UTILITY(U,$J,358.3,11766,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11766,1,3,0)
 ;;=3^Isolated proteinuria w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,11766,1,4,0)
 ;;=4^N06.1
 ;;^UTILITY(U,$J,358.3,11766,2)
 ;;=^5015550
 ;;^UTILITY(U,$J,358.3,11767,0)
 ;;=N06.2^^46^573^35
 ;;^UTILITY(U,$J,358.3,11767,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11767,1,3,0)
 ;;=3^Isolated proteinuria w/ diffuse membranous glomerulonephritis
 ;;^UTILITY(U,$J,358.3,11767,1,4,0)
 ;;=4^N06.2
 ;;^UTILITY(U,$J,358.3,11767,2)
 ;;=^5015551
 ;;^UTILITY(U,$J,358.3,11768,0)
 ;;=N06.3^^46^573^36
 ;;^UTILITY(U,$J,358.3,11768,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11768,1,3,0)
 ;;=3^Isolated proteinuria w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,11768,1,4,0)
 ;;=4^N06.3
 ;;^UTILITY(U,$J,358.3,11768,2)
 ;;=^5015552
 ;;^UTILITY(U,$J,358.3,11769,0)
 ;;=N06.4^^46^573^34
 ;;^UTILITY(U,$J,358.3,11769,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11769,1,3,0)
 ;;=3^Isolated proteinuria w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,11769,1,4,0)
 ;;=4^N06.4
 ;;^UTILITY(U,$J,358.3,11769,2)
 ;;=^5015553
 ;;^UTILITY(U,$J,358.3,11770,0)
 ;;=N06.5^^46^573^37
 ;;^UTILITY(U,$J,358.3,11770,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11770,1,3,0)
 ;;=3^Isolated proteinuria w/ diffuse mesangiocapillary glomrlneph
 ;;^UTILITY(U,$J,358.3,11770,1,4,0)
 ;;=4^N06.5
 ;;^UTILITY(U,$J,358.3,11770,2)
 ;;=^5015554
 ;;^UTILITY(U,$J,358.3,11771,0)
 ;;=N06.6^^46^573^32
 ;;^UTILITY(U,$J,358.3,11771,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11771,1,3,0)
 ;;=3^Isolated proteinuria w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,11771,1,4,0)
 ;;=4^N06.6
 ;;^UTILITY(U,$J,358.3,11771,2)
 ;;=^5015555
 ;;^UTILITY(U,$J,358.3,11772,0)
 ;;=N06.7^^46^573^33
 ;;^UTILITY(U,$J,358.3,11772,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11772,1,3,0)
 ;;=3^Isolated proteinuria w/ diffuse crescentic glomerulonephritis
 ;;^UTILITY(U,$J,358.3,11772,1,4,0)
 ;;=4^N06.7
 ;;^UTILITY(U,$J,358.3,11772,2)
 ;;=^5015556
 ;;^UTILITY(U,$J,358.3,11773,0)
 ;;=N06.8^^46^573^40
 ;;^UTILITY(U,$J,358.3,11773,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11773,1,3,0)
 ;;=3^Isolated proteinuria w/ other morphologic lesion
